MHRA to shed a fifth of its workforce in post-Brexit cost cutting driveBMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n1918 (Published 30 July 2021) Cite this as: BMJ 2021;374:n1918
- Gareth Iacobucci
- The BMJ
The UK’s drug and medical devices regulator is to lose a substantial number of staff as part of a post-Brexit restructure, The BMJ has learned.
The Medicines and Healthcare Products Regulatory Agency (MHRA), which employs around 1200 people in England, could cut its workforce by as much as 20% as part of a transformation programme that will radically reshape how the agency operates, leaked documents seen by The BMJ show. The agency is targeting savings after losing a substantial amount of funding from the European regulatory system after the UK’s exit from the European Union.
The documents reveal details of a voluntary exit scheme that MHRA is offering to staff from its divisions on vigilance and risk management of medicines, licensing, devices, inspection enforcement and standards, as well as its committee secretariat.
A document marked “official sensitive,” seen by The BMJ, said that the MHRA’s income is expected to reduce by 15-20% in next financial year and beyond, while …